A bivalent protein targeting glycans and HR1 domain in spike protein potently inhibited infection of SARS-CoV-2 and other human coronaviruses
Yanxing Cai(Fudan University), Shibo Jiang(Shanghai Medical College of Fudan University), Wei Xu(Beijing Geriatric Hospital), Najing Cao(Fudan University), Lu Lu(Shanghai Medical College of Fudan University), Jiayi Tang(Fudan University), Qiaoshuai Lan(Chinese University of Hong Kong)
Cited by 20
Related Papers
Inhibition of SARS-CoV-2 (previously 2019-nCoV) infection by a highly potent pan-coronavirus fusion inhibitor targeting its spike protein that harbors a high capacity to mediate membrane fusion
|Cell Research|2020|1.4k
Fusion mechanism of 2019-nCoV and fusion inhibitors targeting HR1 domain in spike protein
|Cellular and Molecular Immunology|2020|759
Attenuated replication and pathogenicity of SARS-CoV-2 B.1.1.529 Omicron
|RePEc: Research Papers in Economics|0|647
Structure-based discovery of Middle East respiratory syndrome coronavirus fusion inhibitor
|Nature Communications|2014|400